EUCTR2008-007749-29-GB进行中（未招募）不适用
Monotherapy vs Dual Therapy for Initial Treatment for hypertension - Monotherapy vs Dual Therapy for Initial Treatment for hypertension
R&D Department,0 个研究点目标入组 0 人开始时间: 2010年7月29日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Aged 18-79
- •2.Male subjects or female subjects taking adequate contraception such as the oral contraceptive pill, an intra uterine device or who are surgically sterilised or postmenopausal Females.
- •3. Either systolic BP >=150 mmHg or diastolic BP >=95mmHg. Pts may be included if the PI anticipates BP criteria for inclusion will be met at randomisation.
- •4.Either never-treated or received a maximum of one antihypertensive drug.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 0
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •1. SBP > 200 mmHg or DBP > 120 mmHg
- •2.Secondary or accelerated phase hypertension;
- •3.eGFR < 45 mls/min;
- •4.Contra-indication or previous intolerance to any trial therapy
- •5.Failure to record required home BP readings during placebo run-in.
- •6.Significant co-morbidity (investigator opinion but to include alcoholism,
- •terminal illness, documented non-attendance at clinics etc.
- •Diabetes Type 1
- •Plasma K+ outside normal range on two successive measurements during screening
- •Requirement for treatment with =2 drugs (which can be a CCB and/or {ACEi OR ARB OR direct renin inhibitor OR ß-blocker}) in order to reduce blood pressure to =180/120 mmHg
- •Requirement for diuretic therapy
- •Requirement for ACE inhibitor (or ARB) therapy (other than for hypertension)
- •Absolute contra-indications to any of the study drugs (listed on their data-sheet)
- •Current therapy for cancer
- •Anticipation of change in medical status during course of trial (e.g. surgical intervention > 2 weeks convelescence, actual or planned pregnancy)
- •Inability to give informed consent
- •Not on stable doses of all concomitant medications for a minimum of 4 weeks prior to randomisation
- •Participation in a clinical study involving an investigational drug or device within 4 weeks of screening.
- •Any concomitant condition that, in the opinion of the investigator, may adversely affect the safety and/or efficacy of the study drug or severely limit the subject’s lifespan or ability to complete the study (eg, alcohol or drug abuse, disabling or terminal illness, mental disorders).
- •Treatment with any of the following prohibited medications:
- •a.Oral corticosteroids within 3 months of Screening. Treatment with corticosteroids is also prohibited during study participation.
- •b.Acetylsalicylic acid in excess of 325 mg per day.
- •c.Chronic stable or unstable use of non-steroidal anti-inflammatory drugs (NSAIDs) other than acetylsalicylic acid is prohibited. Chronic use is defined as >3 consecutive or nonconsecutive days of treatment per week. In addition, the intermittent use of NSAIDs is strongly discouraged throughout the duration of this study. If intermittent treatment is required, NSAIDs must not be used for more than a total of 2 days. For all subjects requiring analgesic or anti-pyretic agents, the use of paracetamol is recommended during study participation.
- •d.The use of short-acting oral nitrates (eg, sublingual nitroglycerin) is permitted; however, subjects should not take short-acting oral nitrates within 4 hours of Screening or any subsequent study visit.
- •e.The use of long-acting oral nitrates (eg, Isordil) is permitted; however, the dose must be stable for at least 2 weeks prior to Screening and Randomisation.
- •f.The use of sympathomimetic decongestants or ß-agonists is permitted; however, not within 1 week prior to Screening or Randomisation. In addition, use of these medications will be prohibited within 1 day prior to any clinic visit.
- •g.The use of theophylline is permitted; however, the dose must be stable for at least 4 weeks prior to Screening and throughout study participation.
- •h.The use of phosphodiesterase (PDE) type V inhibitors is permitted; however, subjects must refrain from taking these medications within 1 day of Screening or any subsequent study visit.
- •i. The use of alpha-blockers is not permitted – with the exception of afluzosin and tamsulosin for prostatic symptoms
研究者
相似试验
招募中
不适用
Effect of prednisolone (drug) and GCSF (injecting) for alcohol related liver diseaseCTRI/2019/08/020966Institute of Liver and Biliary Sciences
尚未招募
1 期
Comparison between response of one drug and response of two drugs together in treating fungal keratitisCTRI/2020/05/025159Dr Rajendra Prasad Centre for Ophthalmic Sciences
招募中
3 期
Investigation of therapeutic effect and monotherapy with lacosamide compared to carbamazepine in children with epilepsyIRCT20231123060147N1Mazandaran University of Medical Sciences100
招募中
不适用
Effects of dual initial combination therapy with macitentan plus riociguat or macitentan plus selexipag on hemodynamics in patients with pulmonary arterial hypertensioPulmonary arterial hypertensionJPRN-UMIN000035389Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science76
尚未招募
不适用
Helicobacter pylori eradication in childrenDigestive SystemHelicobacter pylori gastritisPaediatricsPACTR201807134057681Pediatric department Faculty of medicine Alexandria university156